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Hospital mortalityObjective: During the COVID-19 pandemic the continuation or cessation of angiotensin-converting
enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) has been contentious. Mechanisms
have been proposed for both beneficial and detrimental effects. Recent studies have focused on mortality
with no literature having examined length of hospital stay. The aim of this study was to determine the
influence of ACEi and ARBs on COVID-19 mortality and length of hospital stay.
Methods: COPE (COVID-19 in Older People) is amulticenter observational study including adults of all ages
admitted with either laboratory or clinically confirmed COVID-19. Routinely generated hospital data were
collected. Primary outcome:mortality; secondary outcomes: Day-7mortality and length of hospital stay. A
mixed-effects multivariable Cox’s proportional baseline hazards model and logistic equivalent were used.
Results: 1371patientswere includedfromelevencentresbetween27thFebruaryto25thApril2020.Median
agewas74years [IQR61–83].28.6%ofpatientsweretakinganACEiorARB.TherewasnoeffectofACEiorARB
on inpatientmortality (aHR = 0.85, 95%CI 0.65–1.11). For those prescribed an ACEi or ARB, hospital staywas
significantly reduced (aHR = 1.25, 95%CI 1.02–1.54, p = 0.03) and in those with hypertension the effect was






P. Braude, B. Carter, R. Short et al. IJC Heart & Vasculature 31 (2020) 100660Conclusions: Patients and clinicians can be reassured that prescription of an ACEi or ARB at the time of
COVID-19 diagnosis is not harmful. The benefit of prescription of an ACEi or ARB in reducing hospital stay
is a new finding.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Throughout the coronavirus pandemic there has been specula-
tion that recovery from COVID-19 may be influenced by drugs
inhibiting the renin-angiotensin-aldosterone system (RAAS) includ-
ing angiotensin-converting enzyme inhibitors (ACEi) and angioten-
sin receptor blockers (ARBs) [1,2]. Risk factors have been identified
as predisposing to poor outcome with COVID-19 including: hyper-
tension, cardiovascular disease, chronic kidney disease and diabetes
[3–5], all ofwhichhave clear indications forACEi orARBprescription
[6–8].Due to thenumerous indications for thesedrugs inchronicdis-
ease management ramipril has become the fourth most commonly
prescribed drug in the UK at 27 million prescriptions [9]. Of inpa-
tients testing positive for SARS-CoV-2 in New York 8.3% and 10.5%
were taking an ACEi or ARB respectively [10]. Teasing out the effect
onCOVID-19recoverydue to thesecomorbidities, ordue to thedrugs
prescribed for them, has not been straightforward. Opinions on
whether to withhold or continue community prescriptions of these
medications during the pandemic have both been debated [11,12].
However, due to a paucity of trial or observational evidence, organi-
sations including the European Society of Cardiology and the Amer-
ican College of Cardiology and the American Heart Association have
advocatedcontinuingACEi andARB therapy toavoiddeteriorationof
a person’s underlying health issues [13–15].
Patients receiving these medications have been hypothesised to
be detrimentally predisposed to infection; SARS-CoV-2 spike pro-
tein attaches to target cells by binding to the ACE2, which is upreg-
ulated with ACEi and ARBs in animal models [11,16]. However, this
remains controversial in humans, for example in a cohort of
patients with heart failure, ACE2 was not found to be altered by
ACEi or ARBs [17]. In contrast, beneficial effects of ACEi and ARBs
have been proposed mediated via changes in both the innate and
adaptive immune responses occurring within the RAAS [18,19].
A New York database study and an Italian registry study have
shown no increased rate of admissions in those taking an ACEi or
ARB in propensity matched cohorts of admitted patients, inferring
that there is no increased predisposition to COVID-19 [10,20]. One
Chinese multicentre study has shown a mortality benefit in COVID-
19 positive patients who were taking ACEi or ARB for hypertension
[21]. A recent meta-analysis including 9890 patients across 10
studies showed a similar risk of dying from COVID-19 in those tak-
ing and not taking these drugs [22]. None of these studies have
examined the effects of ACEi and ARB on non-mortality process
outcomes such as length of stay.
2. Objectives
The primary aim was to investigate the influence of ACEi and




These data were obtained as part of a prospective multicentre
observational study: the COPE study (COVID-19 in Older People
study). Authority in the United Kingdom to conduct the study2
was granted by the Health Research Authority (20/HRA/1898)
and in Italy by the Ethics Committee of Azienda Policlinico Hospital
Modena (Reference 369/2020/OSS/AOUMO). Cardiff University
acted as study sponsor. This manuscript follows the STROBE state-
ment. The study protocol was written prior to including partici-
pants [23]. The hospitals included were part of a remobilised
research network investigating frailty in emergency laparotomy -
the Older Persons Surgical Outcomes Collaboration (OPSOC) [24].3.2. Setting
Ten hospitals in the United Kingdom participated (Ysbyty
Ystrad Fawr in Caerphilly, Royal Gwent Hospital in Newport,
Neville Hall Hospital in Abergavenny, Southmead Hospital in Bris-
tol, Aberdeen Royal Infirmary, Royal Alexandra Hospital Paisley,
Inverclyde Royal Hospital, Salford Royal, Glasgow Royal Infirmary,
and the University Hospital of Wales in Cardiff) and one in Italy
(University Hospital of Modena Policlinico). The study collected
routinely generated hospital data which were anonymised prior
to analysis. Data were recorded securely at the sites and trans-
ferred in anonymised format to King’s College London for analysis.3.3. Participants
Patients 18 years old admitted to hospital with laboratory or
clinically diagnosed COVID-19 were eligible for inclusion. There
were no exclusion criteria. Convenience sampling was undertaken
from hospital admission lists which were screened by the local
clinical teams. Data were collected from 27th February to 25th
April 2020.3.4. Variables
The primary outcome was inpatient mortality. The time to out-
come (death or discharge) was measured from patient admission,
or the date of diagnosis (if diagnosis was five or more days after
admission to take into account hospital acquired COVID-19).
Patients’ outcomes of discharged and mortality were censored on
the date of each.
Secondary outcomes included: length of hospital stay and Day-
7 mortality. Outcomes were assessed up to 25th April 2020 using
paper and electronic health records. Demographics collected
included age, sex, presence of clinical characteristics documented
in the patient’s health record: coronary artery disease (CAD), dia-
betes, hypertension, smoking status, and reduced kidney function.
C-reactive protein (CRP) was collected as a marker of disease sever-
ity. Both ACEi and ARB medication doses were recorded and cate-
gorised into low and high dose (low dose = as per the British
National Formulary initial dose or below maintenance dose; high
dose = equal or greater than maintenance dose). Doses for hyper-
tension in adults 18–75 years old were used if the British National
Formulary (BNF) stated more than one indication or specific age
group for a drug [25,26]. Sacubitril–valsartan was classified as an
ARB.
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Patients were involved in discussion with the study conception
and development of the protocol.3.6. Bias
A standardised case report form was used at all sites. All study
personnel underwent data collection training under the supervi-
sion of each site’s principal investigator.3.7. Data analysis
We summarised the baseline variables and outcomes using
descriptive statistics. Missing smoking status was imputed in 19
cases as never smokers, and 31 cases of missing CRP were imputed
as not elevated CRP. The primary outcome was analysed as the
time to mortality. Secondary outcome events included time in days
to discharge and Day-7 mortality. Patients who remained in hospi-
tal, but had not reached their seventh day of admission by the end
of the data collection period, were excluded from the Day-7 anal-
ysis. Each time to event analysis was reported with a Kaplan-
Meier survival plot.3.8. Statistical methods
The primary outcome of time to mortality was analysed with a
mixed-effects multivariable Cox’s proportional baseline hazards
model. The analysis was fitted with a random effect for site to
account for variation occurring at each hospital, and adjusted for
patient age group (64, 65–79, 80 years old), sex, disease sever-
ity at presentation (elevated CRP > 40 mg/L); diabetes (yes / no);
hypertension (yes / no); CAD (yes / no), and kidney disease
(eGFR > 60 ml/min/1.73 m2 / 60 ml/min/1.73 m2). Both a crude
hazard ratio (HR), and adjusted hazard ratio (aHR) were estimated.
The baseline proportionality assumption was tested visually using
log-log residuals.
Secondary outcomes were Day-7 mortality (dead / alive), and
the length of hospital stay (measured using time-to discharge).
Day-7 mortality was analysed using a mixed-effects multivariable
logistic regression model, fitting each site as a random effect to
account for variation across hospitals, and adjusted with covariates
consistent with the primary outcome. The length of stay was anal-
ysed using a multivariable Cox model consistent with the primary
outcome. Adjusted odds ratio (aOR), and aHR were estimated
alongside associated 95% confidence interval. To explore moderat-
ing effects in subgroups, the adjusted multivariable analyses were
partitioned by: hypertension; diabetes; CAD; kidney disease;
patient age; sex; smoking status. Analysis was carried out using
Stata version 15. Kaplan Meier survival plots were visualised in
R, with packages survival and survminer.4. Results
4.1. Participants
We screened 1447 participants from all medical and surgical
admissions. 76 participants were excluded due to: no positive lab-
oratory polymerase chain reaction result or clinical diagnosis of
COVID-19 found (n = 60), and access not granted to records
(n = 16). The study included a total of 1371 participants, of which
1124 (89.0%) patients were from the UK and 150 (11%) from Italy
(Table 1). There were 63 patients still in hospital with less than
seven days follow-up that were excluded from the Day-7 mortality3
analysis. The main study findings have been reported with an anal-
ysis looking at frailty in a separate publication [27].4.2. Descriptive data
The population median age was 74 years old (IQR, 61–83) with
a similar number of participants between the age groups. 560 par-
ticipants were female (40.9%) and 100 (7.3%) were current smokers
(Table 1). Of comorbidities collected 706 (51.5%) had hypertension,
493 (36.3%) had kidney disease, 372 (27.2%) had diabetes, and 299
(21.9%) had CAD. Of the included patients 363 (26.5%) died in hos-
pital. The median survival time from admission for those who died
in hospital was 6 days (IQR, 3–11 days; longest time to death was
38 days), and for those alive (i.e. those who were discharged or
censored, when last known alive, and in hospital) was 12 days
(IQR, 6–19 days).
A RAAS drug was prescribed for 392 (28.6%) patients, of which
271 (19.8%) were prescribed an ACEi, and 121 (8.8%) an ARB. The
most frequently prescribed ACEi was ramipril for 181 patients
and ARB was losartan for 48 patients. When dichotomised by dose,
we estimate that approximately 185 patients were prescribed a
low dose ACEi or ARB, versus 207 prescribed a high dose (Supple-
mentary Table 1), dose is only presented descriptively.4.3. Mortality and length of stay
ACEi or ARBs were not associated with inpatient mortality, Day-
7 mortality rate (Table 2). However, they were associated with a
reduced length of stay. Older age, kidney disease, and elevated
CRP were associated with worse outcomes: inpatient mortality,
increased Day-7 mortality, and increased length of stay. Presence
of CAD was associated with increased Day-7 mortality and
increased length of stay. Diabetes mellitus was associated with
increased length of stay only. Hypertension and smoking status
had no association with any outcome.
In the crude analysis mortality there was no crude association
between ACEi or ARB prescription and mortality (HR = 1.01, 95%
CI 0.80–1.28, p = 0.91). Of the other covariates, mortality was asso-
ciated with older age (compared to under 65; 65–79 years old,
HR = 3.22, 95%CI 3.27–4.57, p < 0.001; and 80 and older,
HR = 4.04, 95%CI 2.86–5.71, p < 0.001; see also Supplementary Fig-
ure 1), CAD (HR = 1.60, 95%CI 1.27–2.02, p < 0.001), elevated CRP
(HR = 2.38, 95%CI 1.77–3.21, p < 0.001), and kidney disease
(HR = 1.93, 95%CI 1.55–2.40, p < 0.001) (Table 3).
In the multivariable analysis there was no independent associ-
ation between ACEi or ARB prescription and mortality (aHR = 0.85,
95%CI 0.65–1.11, p = 0.23). In the other covariates increased risk of
mortality was associated with older age (compared to under 65;
65–79 years old, aHR = 3.19, 95%CI 2.22–64.58, p < 0.001; 80 and
older, aHR = 4.02, 95%CI 2.79–5.80, p < 0.001), kidney disease
(eGFR < 60 ml/min/1.73 m2, aHR = 1.55; 95%CI 1.23–1.94), and ele-
vated CRP (aHR = 2.70, 95%CI 2.00–3.64, p < 0.001). There was a
suggested association between mortality and CAD (aHR = 1.27,
95%CI 0.99–1.64, p = 0.06).
There was no main effect of ACEi or ARB on Day-7 mortality
(aOR = 0.82, 95%CI 0.54–1.23, p = 0.16). Of the other covariates
older patients had an increased odds of mortality (Table 3). Com-
pared to those aged under 65, patients aged 65–79 had an
increased odds of mortality (aOR = 3.45, 95%CI 2.03–5.88,
p < 0.001), as well as those aged 80 years and older (aOR = 5.58,
95%CI 3.26–9.57, p < 0.001). There was an increased odds of Day-
7 mortality in patients with CAD (aOR = 1.50, 95%CI 1.02–2.22,
p = 0.05), kidney disease (aOR = 1.87, 95%CI 1.31–2.67,
p < 0.001), and elevated CRP (aOR = 5.51, 95%CI 3.28–9.24,
p < 0.001).
Table 1
Demographic characteristics of the included participants (Note: longest time to
mortality was 38 days).
Inpatient mortality
Dead Alive Total
Sites (n = 363) (n = 1008) (n = 1371)
Hospital A 12 (14.1) 73 (85.9) 85 (6.2)
Hospital B 12 (30.0) 28 (70.0) 40 (2.9)
Hospital C 33 (23.4) 108 (76.6) 141 (10.3)
Hospital D 8 (18.6) 35 (81.4) 43 (3.1)
Hospital E 15 (14.4) 89 (85.6) 104 (7.6)
Hospital F 21 (14.0) 129 (86.0) 150 (10.9)
Hospital G 17 (29.3) 41 (70.7) 58 (4.2)
Hospital H 86 (42.6) 116 (57.4) 202 (14.7)
Hospital I 117
(31.2)
258 (68.8) 375 (27.4)
Hospital J 42 (24.3) 131 (75.7) 173 (12.6)
Age
Under 65 yrs 45 (10.6) 380 (89.4) 425 (31.0)
65 to 79 yrs 139
(29.8)
328 (70.2) 467 (34.1)
Over 80 yrs 179
(37.4)




418 (74.6) 560 (40.9)
Male 221
(27.3)




546 (75.3) 725 (52.9)
Ex smokers 158
(30.0)
369 (70.0) 527 (39.8)
Current smokers 20 (20.0) 80 (80.0) 100 (7.3)




743 (74.7) 995 (72.6)
Yes 110
(29.6)
262 (70.4) 372 (27.1)




500 (75.5) 662 (48.3)
Yes 200
(28.3)
506 (71.7) 706 (51.5)








187 (62.5) 299 (21.8)
Missing 1 2 3
Elevated CRP > 40 mg/L
No 44 (12.2) 318 (87.8) 362 (28.7)
Yes 308
(31.5)
670 (68.5) 978 (71.3)
Missing 11 20 31




692 (80.0) 865 (63.1)
Yes 184
(37.3)
309 (62.7) 493 (36.0)




722 (73.8) 979 (71.4)
Low Dose ACE 36 (28.8) 89 (71.2) 125 (9.1)
High Dose ACE 38 (26.0) 108 (74.0) 146 (10.7)
Low Dose ARB 17 (28.3) 43 (71.7)) 60 (4.4)
High Dose ARB 15 (24.6) 46 (75.4) 61 (4.4)
& Dosage is presented descriptively only.
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The prescription of an ACEi or ARB offered evidence of a protec-
tive effect, and was associated with a shorter length of stay
(aHR = 1.25, 95%CI 1.02–1.54, p = 0.03). There was a longer length
of stay in patients that were: older (65–79 years old, aHR = 0.68,
95%CI 0.56–0.83, p < 0.001; 80 years old, aHR = 0.50, 95%CI
0.40–0.64, p < 0.001); had a greater disease severity at presentation
(CRP > 40 mg/L, aHR = 0.81, 95%CI 0.68–0.97, p = 0.02); and had
diabetes (aHR = 0.82, 95%CI 0.67–1.00, p = 0.05).
Due to our incomplete understanding of the disease, and mixed
findings in other literature regarding ACEi and ARB prescriptions,
we explored subgroup analyses (Supplementary Figures 2–4). A
protective effect was demonstrated for ACEi and ARB prescriptions
in hypertensive patients with a shorter length of stay (aHR = 1.39,
95%CI 1.09–1.77, p = 0.007, Supplementary Figure 4). There was a
suggested finding of an ACEi or ARB prescription being moderated
by the influence of smoking status: length of stay was reduced in
ex-smokers prescribed an ACEi or ARB (aHR = 1.46, 95%CI 1.08–
1.98, p = 0.015); with a stronger effect seen in current smokers
(aHR = 3.26, 95%CI 1.16–9.18, p = 0.025). However, caution is
needed when interpreting all subgroup analyses5. Discussion
5.1. Key results
These data show that ACEi and ARBs were not associated with
increased mortality in a hospital population admitted with a diag-
nosis of COVID-19. Furthermore, patients taking an ACEi or ARB
had a reduced length of stay, and this was seen with greater effect
in patients with hypertension, independent of age, other comor-
bidities or disease severity.5.2. Mortality
Our demonstration of no difference in mortality between the
ACEi/ARB and non-ACEi/ARB groups admitted with COVID-19 is
in keeping with other studies [28,22]. We have demonstrated a
protective effect with a reduction in Day-7 mortality for patients
with hypertension taking an ACEi or ARB. This fits with another
multi-centre study in China showing similar mortality reductions
at 28-day follow-up. However, compared to our study, their
reported overall mortality rate was far lower (28.3% vs 8.8% respec-
tively). This may have been due to a due to a younger cohort (me-
dian 74 [IQR 61–83] vs 64 [IQR 55–68] respectively) with fewer
comorbidities [21], at a different stage of the pandemic.5.3. Length of hospital stay
We are the first to show that ACEi or ARB prescription has been
linked to a reduction in the length of stay. Rapid discharge may
represent either a marker of better disease recovery, or improve-
ment in unmeasured factors that facilitate discharge from hospital
service such as more rapid normalisation of oxygen saturations.
The virus likely causes inactivation of ACE2, as has been see for
SARS-CoV, and leads to an increase in angiotensin II (Ang II), which
in turn acts via the angiotensin II type 1a receptor (AT1aR) to result
in pulmonary vasoconstriction and increased lung endothelial per-
meability. This precipitates acute lung injury and potentially acute
respiratory distress syndrome [29]. The reduced length of stay in
all patients may be due to the fact that ACEi decreases Ang II pro-
duction, by blocking the conversion of Ang I to Ang II, and ARBs
block AT1aR preventing Ang II’s actions, both theoretically result-
ing in a lower degree of lung injury, and faster recovery. However,
despite this faster hospital recovery the overall physiological
Table 2
Analysis of the time from admission to inpatient mortality.
Time to mortality
Crude Hazard Ratio (HR) Adjusted Hazard Ratio (aHR)&
(n = 1338)
(n = 1342)&& (n = 1326)&&&
HR, (95%CI) p-value aHR, (95%CI) p-value
ACEi/ARB 1.01, (0.80–1.28) 0.91 0.85, (0.65–1.11) 0.23
Age
<65 years Ref
65–79 3.22, (2.27–4.57) <0.001 3.19, (2.22–4.58) <0.001
80 and older 4.04, (2.86–5.71) <0.001 4.02, (2.79–5.80) <0.001
Sex (Female)
Male 1.03, (0.82–1.28) 0.81 1.04, (0.82–1.31) 0.74
Smoking Status (Never) Ref
Ex-smoker 1.17, (0.94–1.45) 0.16 0.94, (0.75–1.18) 0.59
Current 0.76, (0.47–1.24) 0.28 0.92, (0.56–1.52) 0.76
Diabetes 1.06, (0.84–1.34) 0.61 1.07, (0.84–1.38) 0.57
Coronary Artery Disease 1.60, (1.27–2.02) <0.001 1.27, (0.99–1.64) 0.06
Hypertension 1.17, (0.94–1.45) 0.15 0.95, (0.75–1.20) 0.67
Kidney disease (eGFR < 60 ml/min/1.73 m2) 1.93, (1.55–2.40) <0.001 1.55, (1.23–1.94) <0.001
Elevated CRP (>40 mg/L) 2.38, (1.77–3.21) <0.001 2.70, (2.00–3.64) <0.001
& The multivariable regression were adjusted for: age group; sex; smoking status; CRP; diabetes; CAD; hypertension; kidney disease and ACEi/ARB.
&& 29 Cases were not included in the analysis due to patient death on admission.
&&& 16 Cases were not included in the analysis due to missing covariate data.
Table 3
Secondary outcomes: Day-7 Mortality and Time to discharge (length of stay).
Day-7 mortality Length of stay
Adjusted Odds Ratio (aOR)& Adjusted Hazard Ratio (aHR)&
(n = 1338)
(n = 1291)&& (n = 1326)&&&
aOR, (95%CI) p-value aHR, (95%CI) p-value
ACEi/ARB 0.82 (0.54–1.23) 0.34 1.25, (1.02–1.54) 0.03
Age
<65 years Ref
65–79 3.45 (2.03–5.88) <0.001 0.68, (0.56–0.83) <0.001
80 and older 5.58 (3.26–9.57) <0.001 0.50, (0.40–0.64) <0.001
Sex
Male 0.91 (0.64–1.30) 0.60 1.01, (0.85–1.21) 0.89
Smoking Status (Never) Ref
Ex-smoker 1.11 (0.78–1.59) 0.55 0.91, (0.76–1.08) 0.27
Current 0.90 (0.40–2.03) 0.80 0.95, (0.68–1.32) 0.74
Diabetes 1.20 (0.82–1.76) 0.36 0.82, (0.67–1.00) 0.05
Coronary Artery Disease 1.50 (1.02–2.22) 0.04 1.00, (0.80–1.26) 0.99
Hypertension 0.88 (0.61–1.27) 0.50 1.12, (0.94–1.37) 0.21
Kidney disease (eGFR < 60 ml/min/1.73 m2) 1.87 (1.31–2.67) 0.001 0.88, (0.72–1.07) 0.19
Elevated CRP (>40 mg/L) 5.51 (3.28–9.24) <0.001 0.81, (0.68–0.97) 0.02
&&The multivariable regression were adjusted for: age group; sex; smoking status; CRP; diabetes; CAD; hypertension; kidney disease and ACEi/ARB.
&&&63 cases were excluded as the patient was followed up for less than 7 days and was alive and in hospital, and a further 17 cases were not included due to missing covariate
data.
&&&29 cases were not included due to patient death on admission, and 16 cases were not included in the analysis due to missing covariate data.
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from COVID-19.
It is difficult to propose a mechanism that explains the consis-
tent effect of ACEi and ARB improving outcomes for hypertensive
patients that is not seen in other comorbidity groups. This may
demonstrate better medical optimisation preventing significant
inpatient events and so allowing more rapid recovery from
COVID-19. In addition, non-prescription of an ACEi or ARB may
represent a patient group that has not presented to medical
services recently, or has ceased the drug, and therefore has5
undiagnosed or poorly optimised comorbidities (e.g. CAD); this
study would be unable to detect this difference.
5.4. Strengths and limitations
These data were collected through a collaborative of ten repre-
sentative hospitals across the UK and included one Italian hospital.
Bias of data collection was minimised by the collaborative’s estab-
lished record in collecting multisite observational data [24], as well
as delivery of training to new contributing researchers. Patients
P. Braude, B. Carter, R. Short et al. IJC Heart & Vasculature 31 (2020) 100660were only included in this study if they were admitted to hospital.
This would have precluded community cases who never presented
to hospital due to COVID-19 being either less severe or fatal. We
may have overestimated our COVID-19 population through inaccu-
rately diagnosed clinical disease. However this methodology of
inclusion has been used in other COVID-19 studies [30]. Unmea-
sured factors included socioeconomic status, ethnicity, and escala-
tion decisions including intensive care admission. Data were only
collected on the presence of an ACEi or ARB on admission, with
no data collected on whether the drug was continued during hos-
pital stay. The study did not collect data on other cardiovascular
medications that may influence outcome from COVID-19 which
has been borne out in other studies; the use of B-blockers has been
associated with lower likelihood of having a positive COVID-19
test, which may have been co-prescribed with ACEi and ARB
[10]; being prescribed any antihypertensive drug has been shown
to be protective of mortality from COVID-19, without ACEi and
ARB being significant [31].5.5. Interpretation
These results provide reassurance that patients on an ACEi or
ARB at the point of COVID-19 diagnosis is not harmful. As with
other studies we found factors that predisposed to higher mortality
independent of ACEi or ARB prescription, including being over
65 years old, and having either kidney disease or CAD. In addition,
clear differences in mortality outcomes were demonstrated
between the age groups of <65, 65–79 and >80 years old. Disease
severity at presentation as measured by CRP was associated with
higher mortality.5.6. Generalisability
Our results have good generalisability across the UK covering
three out of the four comprising countries – England, Wales and
Scotland. They also represent a large sample of patients. Our inpa-
tient mortality rate is higher than other studies and requires fur-
ther examination to determine whether this is in relation to a
higher threshold for admission to UK hospitals, patients having
higher severity of illness, differences in therapy received, or more
predisposing factors e.g. older and more comorbid.
The prevalence of prescription of ACEi and ARBs in our COVID-
19 cohort was higher than other reported populations, potentially
representing more comorbidity with a greater frequency for ACEi
and ARB indication, and prescribing practice associated with differ-
ing healthcare systems (COPE: ACEi 19.8%, ARB 8.8%; Italy: ACEi
23.9%, ARB 22.2% [20]; New York: 8.3%, ARB 10.5% [10]; China:
ACEi and ARB grouped 5% [21]). These results may not be general-
isable to non-hospitalised COVID-19 patients where a community
versus hospital based COVID-19 study reported a lower commu-
nity comorbidity burden and rate of ACEi / ARB prescription
[20,32].6. Conclusion
This study provides reassurance to clinicians to continue ACEi
and ARBs despite the risk of exposure to COVID-19. However, those
patients that are more likely to receive either an ACEi or ARB -
older patients with comorbidity - remain at higher risk of poor out-
come from COVID-19. Whilst we have reported a shorter length of
stay associated with ACEi or ARB these results do not endorse the
universal prescription of an ACEi or ARB as protective drugs in
COVID-19.6
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